JH

Jochen Huber

SA Sanofi-Aventis: 5 patents #260 of 1,008Top 30%
BO BOE: 2 patents #5,928 of 12,373Top 50%
AG Aventis Pharma Deutschland Gmbh: 1 patents #209 of 418Top 50%
SA Sanofi-Aventis: 1 patents #285 of 563Top 55%
📍 Mittelbiberach, DE: #17 of 56 inventorsTop 35%
Overall (All Time): #532,008 of 4,157,543Top 15%
9
Patents All Time

Issued Patents All Time

Showing 1–9 of 9 patents

Patent #TitleCo-InventorsDate
12226411 Soluble guanylate cyclase activators for treating portal hypertension Judith Maria Ertle, Leo John SEMAN 2025-02-18
11690848 Alkoxy pyrazoles as soluble guanylate cyclase activators Judith Maria Ertle, Ruediger Streicher 2023-07-04
8772469 Synthetic double-stranded oligonucleotides for specific inhibition of gene expression Eugen Uhlmann, Niki Gunkel, Sandra Neumann 2014-07-08
7910602 Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1 Henning Steinhagen, Kurt Ritter, Bernard Pirard, Kirsten BJERGARDE, Marcel Patek +2 more 2011-03-22
7635769 Oligoribonucleotide derivatives for specific inhibition of gene expression Eugen Uhlmann, Niki Gunkel, Sandra Neumann 2009-12-22
7514423 Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases Stefan Schafer, Wolfgang Linz, Markus Bleich 2009-04-07
7279286 High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity Aimo Kannt, Antje Pommereau, Harald Thuering, Martin Oppermann 2007-10-09
7169612 Use of EDG2 receptor in an animal model of heart failure Evi Kostenis, Paulus Wohlfart, Kai Rosport, Andreas Bueltmann, Christine Baumgartner +2 more 2007-01-30
6930103 Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases Stefan Schafer, Wolfgang Linz, Markus Bleich 2005-08-16